The Antibacterial Effects of Antimicrobial Peptides OP-145 against Clinically Isolated Multi-Resistant Strains.
Ming. Liu L; Huang. Jian-An JA
Key Findings
- OP-145 killed 9 out of 10 MRSA strains in lab tests
- It significantly lowered bacterial counts in biofilms after 24 hours
- The peptide shows promise as a new type of antibacterial agent against drug‑resistant infections
Practical Outcomes
- While the results are encouraging, OP-145 is still an experimental compound and not available for personal use. Biohackers should view this as early‑stage evidence that LL‑37‑based peptides might become future anti‑infection tools, but more research and clinical trials are needed before any DIY protocols can be safely designed.
Summary
Researchers tested a lab-made peptide called OP-145, which is based on the natural human peptide LL‑37, and found it can kill most of the tested drug‑resistant Staph bacteria and break down the protective slime they form.
Abstract
OP-145 is a synthetic antimicrobial peptide developed from the human cathelicidin LL-37. The purpose of this investigation was to evaluate the effect of the antimicrobial peptide OP-145 against clinically isolated drug-resistant strains. Ten methicillin-resistant Staphylococcus aureus (MRSA) strains were obtained from our hospital's clinical inspection center, and the activity of OP-145 on growth and biofilm formation of these strains was evaluated by colony counts and scanning electron microscopy. The antimicrobial peptide OP-145 showed significant antibacterial activity against 9 MRSA strains. For the biofilm experiments, MRSA counts in the biofilms decreased significantly after 24 h (P ＜ 0.05). OP-145 strongly reduced growth and biofilm formation of clinically isolated drug-resistant strains in vitro, and the use of this class of antimicrobial agents may be an important new approach in controlling bacterial infections.
Study Information
pubmed
2017
2017-09-11T00:00:00.000Z
10.7883/yoken.jjid.2017.090